484 Effect of Longer-Term Administration of Evolocumab in Patients With Angiographic Coronary Artery Disease: Results of the GLAGOV Open Label Extension Study - 02/12/20
Doi : 10.1016/j.hlc.2020.09.491
S. Nicholls 1, T. Anderson 2, C. Ballantyne 3, L. Cho 4, J. Kastelein 5, W. Koenig 6, T. Hucko 7, H. Kassahun 7, Y. Liu 7, H. Wang 7, S. Nissen 4
1 MonashHeart, Monash Cardiovascular Research Centre, Monash University, Clayton, Australia
2 Libin Cardiovascular Institute, University of Calgary, Calgary, Canada
3 The Methodis DeBakey Heart and Vascular Center, Section of Cardiovascular Research, Baylor College of Medicine, Houston, USA
4 Department of Cardiovascular Medicine, Cleveland Clinic Coordinating Center for Clinical Research, Cleveland, USA
5 Academic Medical Center, Department of Vascular Medicine, University of Amsterdam, Amsterdam, The Netherlands
6 Deutsches Herzzentrum München, Technische Universität München, München Germany and DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Germany; Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany
7 Clinical Development, Amgen Inc., Thousand Oaks, USA
Le texte complet de cet article est disponible en PDF.
Plan
© 2020
Publié par Elsevier Masson SAS.
Vol 29 - N° S2
P. S255 - 2020 Retour au numéro
Article précédent
- 483 Economic Evaluation of the ORBITA Trial, in the Australian Context
- V. McCreanor, A. Nowbar, C. Rajkumar, A. Barnett, D. Francis, N. Graves, R. Al-Lamee, W. Parsonage
- 485 Effects of Posture and Physical Activity on R-Wave Amplitude in the ConfirmRx Cardiac Monitor
- M. Swale, S. Delacroix, G. Young, V. Paul, L. McSpadden, K. Ryu, D. Di Fiore, M. Santos, I. Tan, A. Conradie, S. Worthley, S. Pavia
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?